Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Adiponectin

Adiponectin

Brief Information

Name:Adiponectin
Target Synonym:30 kDa adipocyte complement-related protein,Adipocyte complement-related 30 kDa protein (ACRP30),Adipocyte, C1q and collagen domain-containing protein,Adipose most abundant gene transcript 1 protein,Gelatin-binding protein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ADQ-H52H3 Human Human Adiponectin Protein, His Tag, premium grade
ADQ-H52H3-structure
ADQ-H52H3-sds
ACRO Quality

Synonym Name

ADIPOQ,Adiponectin,ACDC,ACRP30,APM1,GBP28

Background

Adiponectin is also referred to as GBP-28, APM1, ADIPOQ, ACDC and Acrp30, is a secreted protein which contains one C1q domain (commonly called the globular domain) and onecollagen-like domain. Adiponectin / ADIPOQ is synthesized exclusively by adipocytes and secreted into plasma. ADIPOQ is important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities. Adiponectin antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages, and also by counteracting its effects. Acrp30 Inhibits endothelial NF-kappa-B signaling through a cAMP-dependent pathway and may play a role in cell growth, angiogenesis and tissue remodeling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMW.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
DLBS-3233 DLBS-32; DLBS-3233 Approved Dexa Medica Inlacin India Diabetes Mellitus, Type 2 Dexa Medica 2011-01-01 Prediabetic State; Diabetes Mellitus, Type 2 Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap